Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cadonilimab (AK104) plus axitinib in advanced renal cell carcinoma
CTR20213457Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and axitinib in renal cell carcinoma (RCC), sponsored by Akeso, Inc. Primary endpoints: Objective response rate and Safety. Started Jul 2023; status: completed.
02
Drugs
cadonilimabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20213457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213457.